Revolution Medicines’ Phase 3 RAS inhibitor daraxonrasib delivered a major clinical signal in metastatic pancreatic ductal adenocarcinoma, with top-line results tied to longer survival versus standard chemotherapy. The company’s follow-through was immediate in capital markets, pricing a large concurrent stock and debt offering shortly after the trial readout. The financing and follow-on structure positions Revolution to scale development after the clinical milestone while investors digest efficacy and durability questions typical for RAS-targeted oncology assets. The sequence of trial results followed by a record-sized raise highlights how quickly conviction can translate into funding when late-stage data shift risk perception for hard-to-treat cancers.